Relay Therapeutics CFO Sells 17,717 Shares for $350,000

Thomas Catinazzo, the CFO of Relay Therapeutics, sold 17,717 shares of the company's stock on August 14, 2026, for a total of $350,000. This sale was conducted through a pre-arranged trading plan adopted in October 2025, ensuring structured liquidity unaffected by corporate developments. After the transaction, Catinazzo retains 140,568 shares, representing a 11% reduction in his direct stake.

As of the Aug. 17, 2026 market close, the remaining shares are valued at approximately $2.9 million. Despite the significant increase in the company's stock price over the past year, analysts still expect further gains. The Motley Fool's Stock Advisor analysts rate Relay Therapeutics as a buy, with a median price target of $26, indicating a potential gain of 40.9% from the current stock price.